Silverback: Taking on tumoral myeloid cells

How Silverback’s conjugates activate tumor-specific myeloid cells against cancer

Silverback’s antibody-based conjugates stimulate innate and adaptive immunity by turning myeloid cells against tumors, while overcoming resistance to checkpoint inhibitors and other T cell-targeting immunotherapies.

“When you are able to appropriately and potently activate myeloid cells, the tumor microenvironment is completely reprogrammed,” Valerie Odegard, CSO of Silverback Therapeutics Inc., told BioCentury. “The inflammatory nature of the response allows for T cells and other immune cells to then infiltrate those

Read the full 684 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers